利斯的明透皮贴剂在阿尔茨海默病治疗中的成本效果分析

Cost-effectiveness of Rivastigmine Transdermal Patch in Treating Mild to Moderate Alzheimer's Disease

目的:比较利斯的明透皮贴剂和多奈哌齐片剂治疗阿尔茨海默病的成本效果。方法:分别从全社会角度和支付方角度出发,采用Markov队列模拟进行成本效用分析,循环周期为24周,研究时限为5年。模型参数主要来自临床研究和经济学文献。采用单因素敏感性分析和概率敏感性分析检验结果的稳定性。结果:利斯的明透皮贴剂组的健康产出为2.64质量调整生命年(QALYs);多奈哌齐片剂组为2.11质量调整生命年。基于支付方角度,利斯的明透皮贴剂组的总费用为3.4万元,多奈哌齐片剂组的总费用为6.8万元;基于全社会角度,两组的总费用分别为37.7万元和52.8万元。结论:相对多奈哌齐片剂,利斯的明透皮贴剂的效果更好,成本更低,是具有显著成本效果优势的优选方案。

Objective:to compare the cost-eff ectiveness of Rivastigmine transdermal patch and Donepezil tablet in treating Alzheimer's disease.Methods:from the payers’and social perspectives,using Markov cohort simulation(24 week-per cycle,10 cycles)to conduct the research.Model inputs mainly come from published clinical and economic studies.One-way and probabilistic sensitivity analysis were performed to check the robustness.Results:Rivastigmine transdermal patch group gained 2.64 QALYs,Donepezil tablet group gained 2.11 QALYs.As for the total cost,Rivastigmine transdermal patch group was 34 thousand RMB and Donepezil tablet group was 68 thousand RMB from the payers’perspective.In view of society,the total cost of the two groups were 377 thousand RMB and 528 thousand RMB,respectively.Sensitive analysis showed the result was robust.Conclusion:The available evidence shows that Rivastigmine transdermal patch is a dominating choice,providing greater health gains and lower overall costs than Donepezil.